Investor Relations

Company Overview

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company developing a new class of cancer therapy called PP2A inhibitors. The Company’s innovative approach enhances the efficacy of both chemotherapy and immunotherapy, potentially providing new treatment options for patients. At the core of the Company’s therapy is LB-100, the Company’s proprietary compound that acts as an inhibitor of the PP2A phosphatase with a favorable toxicity profile. LB-100 promotes the production of neoantigens and cytokines, boosts T-cell proliferation, and disrupts the DNA repair mechanisms of cancer cells, potentially improving treatment outcomes. The Company is conducting multiple clinical trials for solid tumors with unmet medical needs. LIXTE’s unique approach has no known competitors and is covered by a comprehensive patent portfolio.

Latest Presentation

Investor Presentation - April 2024

Latest Financial Results

Q3 2023

Quarter Ended Sep 30, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Stock Snapshot

IR Contacts


LIXTE Biotechnology Holdings, Inc.
680 E Colorado Blvd.
Suite 180
Pasadena, CA 91101

Investor Relations

PondelWilkinson Inc.
T: 310-279-5980

Transfer Agent

P.O. Box 43006
Providence RI 02940-3006
T: 781-575-4247